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AbstrAct
Objectives Clinical management of giant cell arteritis 
(GCA) involves balancing the risks and burdens arising 
from the disease with those arising from treatment, but 
there is little research on the nature of those burdens. We 
aimed to explore the impact of giant cell arteritis (GCA) and 
its treatment on patients’ lives.
Methods UK patients with GCA participated in semi-
structured telephone interviews. Inductive thematic 
analysis was employed.
results 24 participants were recruited (age: 65–92 
years, time since diagnosis: 2 months to >6 years). 
The overarching themes from analysis were: ongoing 
symptoms of the disease and its treatment; and ‘life-
changing’ impacts. The overall impact of GCA on patients’ 
lives arose from a changing combination of symptoms, 
side effects, adaptations to everyday life and impacts on 
sense of normality. Important factors contributing to loss of 
normality were glucocorticoid-related treatment burdens 
and fear about possible future loss of vision.
conclusions The impact of GCA in patients’ everyday 
lives can be substantial, multifaceted and ongoing 
despite apparent control of disease activity. The findings 
of this study will help doctors better understand patient 
priorities, legitimise patients’ experiences of GCA and 
work with patients to set realistic treatment goals and plan 
adaptations to their everyday lives.
IntrOductIOn
Giant cell arteritis (GCA) is the the most 
common form of primary systemic vasculitis 
and primarily affects older people.1 2 The 
vasculitic process may result in ischaemic 
manifestations such as anterior ischaemic 
optic neuropathy or jaw claudication, 
which may produce groups of character-
istic symptoms leading to clinical diagnosis. 
Presentation may, however, be non-specific 
with systemic features such as fever and weight 
loss and in this case diagnosis is facilitated by 
laboratory, histological and imaging tests.
The mainstay of treatment remains high-
dose glucocorticoids (initially 40–60 mg of 
prednisone equivalent), aiming to control 
disease activity. The dose is subsequently 
tapered gradually over several years but 
is increased in the face of relapse. Gluco-
corticoid-related adverse effects result 
in considerable morbidity in this patient 
population.3 Thus, clinical management of 
GCA involves a balance between the risks 
and burdens of the disease, and the risks 
and burdens of the treatment. Much has 
been written about this from the medical 
perspective; the sparse literature about 
patient priorities in GCA suggests that 
patient priorities for GCA include vision, 
control of arms and legs and personal care 
abilities.4 Qualitative research to develop 
patient-relevant outcome measures in large-
vessel vasculitis has been conducted with 
patients with Takayasu arteritis, a rarer form 
of large-vessel vasculitis that affects younger 
adults,5 but the experience of older patients 
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Research
strengths and limitations of this study
 ► This study provides the first qualitative analysis of 
the impact of GCA and its treatment on patients’ 
everyday lives.
 ► Two approaches to sampling were adopted in 
recognition that patients associated with the charity 
PMRGCAuk were unlikely to be representative of 
all GCA patients, and we also acknowledge that 
patients who felt that GCA had a large impact on 
their lives may have been more likely to volunteer 
to participate.
 ► Interviews were conducted with a sample of people 
from different social backgrounds and age groups; 
future research might actively aim to recruit people 
from a range of ethnic and cultural groups.
 ► The data presented are based on patients’ 
retrospective accounts of their experiences, which 
may change with time.
 ► Our methods did not allow us to verify the clinical 
diagnosis of GCA from participants’ medical records 
or the results of medical tests they had undergone, 
but the fact that all participants were able to describe 
their glucocorticoid treatment provided reassurance 
that our sampling strategy identified individuals 
from the population of interest.
group.bmj.com on September 12, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Liddle J, et al. BMJ Open 2017;7:e017073. doi:10.1136/bmjopen-2017-017073
Open Access 
with GCA remains relatively unexplored. According to 
Borg and Davidson, ‘when it comes to understanding 
recovery, the trivialities of everyday life must be seen as 
anything but trivial’.6 In order to understand how best 
to help patients recover from their illness, we aimed 
to examine GCA and its treatment from the patient 
perspective, through the lens of its impact on patients’ 
everyday lives.
MethOds
Design
This was a qualitative study using semi-structured tele-
phone interviews and inductive thematic analysis of data. 
The study received ethical approval from Keele Univer-
sity’s Research Ethics Committee (Ref. ERP2254) and 
verbal and written consent was obtained from all partici-
pants (a completed paper consent form was posted back 
to the research team by the participant after each inter-
view).
Participants and data collection
Participants were recruited using two approaches. First, 
letters were sent to patients with GCA who had taken part 
in a cross-sectional survey, recruited through general prac-
tice medical records, and who had consented to further 
contact. Second, an email was circulated by the UK 
charity PMRGCAuk to its regional groups and members, 
inviting patients to contact the research team for further 
information. Only patients who reported that a clinician 
had diagnosed GCA were included. Purposive sampling 
categories included age, gender and time since diagnosis. 
JL and CDM developed a list of topics and prompts to 
guide interview discussions.
Following informed consent, RB conducted and 
audio-recorded semi-structured telephone interviews 
with recruited patients with GCA until the point where the 
research team agreed there were ‘diminishing returns’ 
from further data collection and that data saturation was 
sufficient.7–9 Brief fieldnotes were written after each inter-
view to record thoughts about emerging analytic themes 
and data coding.
Analysis
All interview recordings were transcribed and pseud-
onyms used to preserve participant confidentiality. An 
inductive thematic approach was taken to analysis.10 RB 
completed an initial categorising and line-by-line coding 
of all data from the transcripts using QSR NVivo V.10 and 
discussed the development of codes and themes with JL. 
JL then continued with additional analysis (in discussion 
with JR and CDM), developing codes and themes focusing 
specifically on the impact of symptoms and treatment on 
patients’ everyday lives. After further discussion, JL and 
JR developed a visual representation of these themes 
(figure 1).
results
Participants’ ages ranged from 65 to 92 years and time 
since diagnosis ranged from 2 months to over 6 years. All 
participants were White British (table 1). Interviews lasted 
between 29 and 128 min. One transcript was excluded 
from analysis because the patient contacted the research 
team to say that her diagnosis of GCA had been changed 
to a diagnosis of lymphoma.
Patients did not conceptualise the impact of GCA 
as a set of discrete symptoms or side effects, but as an 
ongoing experience, changing over time, resulting from 
the combination and co-occurrence of multiple factors. 
Figure 1 is a visual representation of subthemes and codes 
within the data, demonstrating the psychological impacts, 
symptoms and side effects that patients experienced, 
and the aspects of their everyday lives requiring adapta-
tion as a result. Patients were often unable to distinguish 
between disease-related symptoms and treatment-related 
side effects and did not make a distinction in terms of 
impact; the impact and combination of the experiences 
was most important to patients, regardless of the cause. 
Presentation of findings reflects this.
Two overarching themes from the qualitative data are 
presented: ongoing symptoms of the disease and its treat-
ment and ‘life-changing’ impacts.
theme 1: ongoing symptoms of the disease and its treatment
Patients gave detailed accounts of the symptoms of their 
disease and its treatment that impacted on their everyday 
lives, ranging from extreme to minimal. The data in 
tables 2 and 3 illustrate the extent to which the experi-
ence of GCA and its treatment varied between patients, in 
both type and duration.
Types of symptoms
"The effects it had on me, my body and my mind as well…"
Fatigue, pain, sight loss, other visual symptoms, changes 
in mood and changes in physical appearance and sleep 
(table 2) were particularly reported as having implica-
tions for the extent to which patients could continue 
living their lives in the same way as they had done before 
the onset of GCA. The experience of permanent visual 
loss was associated with feelings of bereavement and 
vulnerability. Other generalised, persistent symptoms 
such as dizziness and loss of strength were also reported 
by patients.
Duration of impact
“He says, ‘I’m going to give you a course of treatment’, he says, 
‘which is gonna last for some time—more like years than weeks’, 
he says, ‘but it will control it and hopefully we can stop it’.”
The experiences of patients varied widely, with some 
reporting that the impact of GCA and/or its treatment 
on their everyday lives had continued for many years 
after diagnosis (up to 5 years, and longer for those who 
developed new features such as sight loss), while others 
reported that the impact of GCA and/or its treatment on 
their lives had been relatively short-lived.
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Figure 1 This diagram represents the multiple physical and psychological symptoms experienced by patients living with a 
diagnosis of giant cell arteritis (GCA) (inner circle), and the multiple domains of daily living (outer circle) that these symptoms 
can impact on. The arrows denote the rotation of each circle, with the intention of visually representing the ability of individual/
groups of symptoms to impact on multiple domains of daily living. The rotation also indicates the potential for the relative 
importance and impact of each factor to vary over time due to fluctuations in the underlying disease, the dose and duration 
of glucocorticoid treatment, the influence of comorbidities and changes in individual adaptations and approaches to self-
management.
The impact of symptoms could be categorised as: a) 
minimal or no long-term impact; b) continuing symptoms 
over time periods ranging from weeks to years or c) changes 
in health as a result of permanent visual loss and/or new 
health problems that now required management (table 3). 
There were no particular differences between the impacts 
or types of symptoms that were experienced minimally and 
those that became long-term.
Some patients had both long-term and permanent 
impacts. While some of those who experienced long-term 
impacts and symptoms reported that these resolved or 
diminished in the months and years following the initi-
ation of treatment, others had not yet perceived such 
improvements. In particular, the continuation of non-spe-
cific symptoms (table 2) caused confusion and frustration 
for patients, especially in the context of being told that 
their inflammatory marker test results were within the 
normal range.
theme 2: ‘life-changing’ impacts
Patients whose symptoms had resolved quickly did not feel 
that GCA had changed their lives. However, the ongoing 
impacts of GCA symptoms and treatment side effects were 
described as being ‘life changing’ (Cressida, 62, 5 years 5 
months since diagnosis) and ‘restricting my life totally’ 
(Dorothy, 78, 2 years 11 months since diagnosis).
Activities, behaviours and circumstances
"I just used the energy on what I absolutely had to do and 
everything else was on hold"
Those patients with ongoing symptoms of GCA and its 
treatment generally described how these had substan-
tially affected their everyday lives including aspects of life 
such as: work and voluntary roles; relationships; hobbies, 
social and leisure activities; household tasks, daily routines 
and personal care; financial circumstances and driving 
(table 4).
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Table 1 Sociodemographic characteristics of sample 
(n=24)
Male
(%) n=9
Female
(%) n=15
Total
(%) n=24
Age group at interview 
(years)
  60–69 1 (11) 4 (27) 5 (21)
  70–79 7 (78) 9 (60) 16 (67)
  80–89 – 2 (13) 2 (8)
  90–99 1 (11) – 1 (4)
Time since diagnosis 
(months)
  ≤12 – 4 (27) 4 (17)
  13–24 3 (33) 3 (20) 6 (25)
  25–36 4 (44) 3 (20) 7 (29)
  37–48 1 (11) 1 (7) 2 (8)
  49–60 – 2 (13) 2 (8)
  ≥61 1 (11) 2 (13) 3 (13)
Ethnicity/nationality
  White British 9 (100) 15 (100) 24 (100)
Living arrangements
  Alone – 5 (33) 5 (21)
  With one other person 9 (100) 10 (67) 19 (79)
Marital status
  Married/long-term partner 9 (100) 10 (67) 19 (79)
  Single – 2 (13) 2 (8)
  Divorced/separated – 1 (7) 1 (4)
  Widowed – 2 (13) 2 (8)
Current work status
  Retired 9 (100) 12 (80) 21 (88)
  Part-time work – 2 (13) 2 (8)
  Not working for health 
reasons
– 1 (7) 1 (4)
Recruitment source
  Survey 8 (89) 5 (33) 13 (54)
  PMRGCAuk charity 1 (11) 10 (67) 11 (46)
Impacts could be direct (eg, as a result of fatigue or 
visual loss making activities unmanageable) or indirect 
(such as the fluctuating nature and unpredictability 
of symptoms affecting an individual’s ability to plan 
or commit to future activities or events). Both types of 
impact required patients to adapt, consequently losing or 
reducing the sense of normality in their everyday lives. 
Patients also reflected on the feelings of guilt and regret 
that they had when their relationships with other people 
were affected.
Thoughts and feelings
"To be able to live a normal life, I suppose, is the thing that is 
desirable"
Frustration arose as a result of patients being unable to 
continue with activities and tasks in the same way as they 
had before the onset of GCA (table 5). Patients talked 
about how these unwanted adaptations to their everyday 
lives affected the extent to which they felt independent, 
and the need to rely on others or ask for help was partic-
ularly unwelcome. Such reductions in independence or 
being unable to continue with everyday life as normal 
resulted in some patients feeling that they were not 
coping or managing the situation as well as they believed 
they should be able to. Their accounts demonstrated 
tendencies towards self-criticism rather than self-com-
passion, particularly when a less active, less mentally 
positive or less independent role was not congruent with 
their established perceptions of themselves and their 
identity.
Other psychological impacts were also prominent in 
patients’ accounts of living with GCA. These included 
symptoms of low mood or depression mentioned earlier 
(see table 2), but reduced confidence, fear and uncer-
tainty were also common themes in patients’ accounts 
(table 5). Visible bodily changes resulting from glucocor-
ticoid treatment and visual loss were two specific causes 
of feelings of reduced confidence and/or low mood, 
again impacting on perceptions of self and identity. 
While the actual experience of symptoms like perma-
nent visual loss was frightening, being afraid of what 
might happen (ie, losing vision, experiencing a relapse 
of symptoms and of the potential future side effects of 
treatment) was a strong theme in the data. This was not 
exclusive to patients who had experienced ongoing or 
permanent symptoms.
For those who did express fears about the future, these 
fears were compounded by the uncertainty that patients 
felt about the likelihood of events such as visual loss occur-
ring, along with their other unanswered questions about 
whether their symptoms would improve and which of 
their symptoms were due to GCA and/or its treatment or 
other conditions. Reassurance from clinicians sometimes 
helped to reduce anxiety (table 5). However, the lack of 
a clear-cut or predictable relationship between the length 
of time since the onset of symptoms and the impact of 
GCA and its treatment on patients’ lives (table 3) was a 
strong feature in the data.
dIscussIOn
GCA and its treatment present ongoing physical 
and psychological problems for patients, affecting 
their everyday lives in a wide variety of ways. As in a 
recent study of patients with polymyalgia rheumatica, 
another inflammatory condition of older people that is 
primarily treated with glucocorticoids, patients in our 
study described their experience in terms of collective 
impacts, rather than focusing on localised symptoms.11 
Practical, social and psychological support may be valu-
able therapeutic interventions to help patients recover 
or maintain a sense of normality in everyday life tasks, 
skills and activities. Patients will likely view recovery as 
linked with undertaking activities of value and ‘re-assess 
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continually and monitor their current well-being’, 
comparing this with their perceptions of normality 
before diagnosis.12 13
Besides the expected impact of permanent visual loss 
on patients’ lives,14 it is important to note the extent to 
which other symptoms including fatigue, pain and ‘not 
feeling normal’ continued to affect multiple aspects of 
the lives of patients with GCA many years after their 
diagnosis. In addition, psychological consequences such 
as reduced confidence, anxiety and feelings of reduced 
independence could extend beyond the duration of 
the physical symptoms. Thus, the status of a patient in 
terms of coping, recovery and/or sense of normality in 
everyday life is somewhat unpredictable and does not 
necessarily correspond with the length of time since 
diagnosis/completion of treatment or clinical severity.
Ongoing adaptations were made by patients both as a 
direct consequence of their symptoms and as a strategy 
for self-management. Hall et al describe these strategies as 
part of ‘the fight to maintain normality’.12 An increased 
sense of independence may arise from being able to 
plan changes in advance. Furthermore, ‘maintaining 
the appearance of normality’12 can be challenging when 
glucocorticoid treatments cause visible bodily changes, 
impacting on self-image, mood and confidence, with 
resulting effects on activities and behaviours.
Finding the optimal balance of information provision is 
challenging, and by educating patients about the risks of 
visual loss with GCA, an additional psychological burden 
is introduced. GCA presents considerable risks in terms of 
visual loss if left untreated,15 16 consequently clinicians may 
emphasise these risks to maximise patient adherence to 
glucocorticoid treatment. Yet fears about the possibility of 
visual loss can be very distressing for patients, continuing 
long after diagnosis. In our study, patients who had lost 
vision were also concerned about relapse causing further 
visual loss in the future. In addition, changes in vision 
from other conditions such as cataract and glaucoma, 
usually attributed to glucocorticoid therapy, heightened 
patients’ existing anxieties about experiencing perma-
nent visual loss as a result of GCA.
This study provides the first qualitative analysis of the 
impact of GCA and its treatment on patients’ everyday 
lives. Interviews were conducted with a sample of people 
from different social backgrounds and age groups. 
The findings are compatible with existing models of 
health experiences and research from other chronic 
conditions. The data presented are based on patients’ 
retrospective accounts of their experiences, which may 
change with time.
It was not the intention of this study to specifically 
explore ethnic or cultural factors that may impact on 
experiences of GCA, but future research might actively 
aim to recruit people from a range of ethnic groups. In 
addition, the impact of GCA for people of different ages 
and/or before and after transition points in the life-
course such as retirement, and of patients who undergo 
treatment with evolving biologic regimens, could be 
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Table 3 Impact duration of symptoms experienced by patients with treated giant cell arteritis
Minimal or no long-
term impact
They put me straight on to steroids. […] everything disappeared after that. And I’ve had no 
symptoms since.  (Joan, 81, 1 year 4 months since diagnosis)
As far as living with it goes, um to be quite honest I haven’t found any real change um it's not affecting 
me as far as my day to day living what I do and things all the way through. I think I've been very, very 
lucky. (David, 71, 2 years 5 months since diagnosis)
Continuing 
symptoms
I’m past my year’s date of my first pain in my head and I’m not better. I’m worse than I was at the 
start…and really, just the tiredness, legs pain that I’ve told you […] I count these cataracts as the bane 
of my life. (Sheila, 73, 11 months since diagnosis)
I'm pleased, you know, that I've, that I've got through it all. But that was 2010. We're now 2015. So it's 
only in the last, say, year that I've really got my body strong again […] it took a good few years after to 
really get back my strength. (Cressida, 62, 5 years 5 months since diagnosis)
[I] can’t do the things that I want to now […] because of the discomfort in my joints, in my arms and 
even in the chest. It’s really, really uncomfortable […] I believe it’s the reactions from the Prednisolone 
because I, I don’t, I don’t think it’s from the Giant Cell Arteritis […] that seems – after about 2 month, the, 
the headaches went away, although I’ve still got the inflammation in my bloodstream like, according to 
(the rheumatologist), you know but… yeah it’s, it’s the after effects of, of those—of Pred-, Prednisolone 
steroids that I think is causing—this is what’s caused my glaucoma problems as well. (Dennis, 69, 
2 years 6 months since diagnosis)
Changes in health You’ve lived your life with full vision […] It’s really hard. […] because three quarters of the sight has 
gone in my right eye.  (Gloria, 72, 6 years since diagnosis)
I’ve got tablets now… I’m going to have to have long term – you see, I, I, I don’t know—I’m thinking 
I’m going to have to have long term things to, to look after this osteoporosis now. (Laurence, 72, 1 year 
7 months since diagnosis)
explored in the future. The relationship between clin-
ical presentation and/or comorbidities at diagnosis 
and the subsequent impact on life could also usefully 
be explored in more detail through a mixed-methods 
study, particularly given the clinical heterogeneity of 
GCA at diagnosis and the potential mediating factors 
such as treatment timing and approach, and individual 
patient behaviours and psychological responses. This 
could facilitate identification in advance of patients 
at higher risk of impacts such as anxiety and loss of 
normality, who might benefit most from potential 
support or educational interventions.
Two approaches to sampling were adopted in recogni-
tion that those GCA patients who were associated with the 
charity PMRGCAuk were unlikely to be representative of 
all patients with GCA. The sample included patients who 
described minimal impacts, although we acknowledge that 
those patients who felt that GCA had a large impact on their 
lives may have been more likely to volunteer to take part in 
the study. In our view, this does not diminish the importance 
of our findings about the experiences of patients who do 
experience ongoing impacts, despite the fact that the prev-
alence of these experiences has not yet been established in 
larger populations.
Purposive sampling is not intended to be numerically 
representative, but instead allows in-depth exploration 
and insight into experiences of patients. Consequently, 
the use of relative frequencies is avoided in the text to 
avoid confusion. Finally, our methodology did not allow us 
to verify the clinical diagnosis of GCA from participants’ 
medical records or the results of medical tests they had 
undergone; however, the fact that all participants were 
able to describe their glucocorticoid treatment provided 
reassurance that our sampling strategy identified individ-
uals from the population of interest.
cOnclusIOns
This study demonstrates that GCA presents patients with 
considerable ongoing physical and psychological symp-
toms that affect their everyday lives in a wide variety of 
ways. These experiences vary over time according to the 
combination of multiple factors including symptoms, 
side effects, new health conditions and adaptations 
and impacts on normality in everyday life. Visible body 
changes attributed to glucocorticoid therapy and fear of 
future visual loss were important contributors to the loss 
of normality reported by patients.
This new understanding of the impact of GCA on patients’ 
lives has important implications for measurement/capture 
of truly patient-relevant outcomes, both in clinical trials and 
clinical practice. It also suggests that many patients with 
GCA would benefit from additional psychological support, 
whether from peers or professionals.
Clinical management of GCA often focuses on medical 
concepts such as disease activity, relapse, remission and 
the prescribing of further medications to mitigate against 
the consequences of glucocorticoid toxicity.2 We suggest 
that an understanding and acknowledgement of the very 
different ways patients experience GCA and its treatment 
will help clinicians negotiate patient-centred treatment 
plans, including planning adaptations to their lives to 
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gh
 it
 w
as
 o
nl
y 
on
ce
 a
 w
ee
k 
[…
] y
ou
 
ha
ve
 t
o 
ta
ke
 it
 b
ef
or
e 
an
yt
hi
ng
 e
ls
e 
an
d
 n
ot
 h
av
e 
an
yt
hi
ng
 t
o 
d
rin
k 
fo
r 
at
 le
as
t 
ha
lf 
an
 h
ou
r 
an
d
 I 
fo
un
d
 t
ha
t 
re
al
ly
 d
iffi
cu
lt 
b
ec
au
se
 w
he
n 
I w
ak
e 
up
 
I'm
 e
ve
r 
so
 t
hi
rs
ty
 a
nd
 t
o 
ha
ve
 t
o 
ta
ke
 t
hi
s 
p
ill
 a
nd
 t
he
n 
w
ai
t 
ha
lf 
an
 h
ou
r 
b
ef
or
e 
I c
ou
ld
 h
av
e 
a 
cu
p
 o
f t
ea
 I 
fo
un
d
 r
ea
lly
 h
or
rib
le
. (
Ju
ne
, 7
5,
 2
 y
ea
rs
 
si
nc
e 
d
ia
gn
os
is
)
I’v
e 
go
t 
no
 o
st
eo
p
or
os
is
 b
ut
 I 
d
o 
ta
ke
 a
 t
ab
le
t 
ea
ch
 w
ee
k 
fo
r 
th
at
. I
 h
av
e 
to
 t
ak
e 
on
e 
a 
w
ee
k,
 o
n 
th
e 
sa
m
e 
d
ay
, e
ve
ry
 w
ee
k 
an
d
 s
it 
fo
r 
ha
lf 
an
 h
ou
r 
af
te
r 
I’v
e 
ta
ke
n 
it.
 (C
la
re
, 7
5,
 2
 y
ea
rs
 s
in
ce
 d
ia
gn
os
is
)
Ta
b
le
 4
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Fi
na
nc
ia
l 
ci
rc
um
st
an
ce
s
I'm
 n
o
w
 p
ay
in
g
 f
o
r 
so
m
eb
o
d
y 
to
 c
le
an
 t
he
 h
o
us
e.
 T
he
y 
co
m
e 
in
 fo
rt
ni
gh
tly
 a
nd
 h
av
e 
a 
go
od
 g
o 
th
ro
ug
h 
fo
r 
m
e.
 (D
or
ot
hy
, 7
8,
 2
 y
ea
rs
 1
1 
m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
W
el
l f
or
 o
ne
 t
hi
ng
 it
's
 t
he
 c
os
t 
re
al
ly
 o
f e
m
p
lo
yi
ng
 p
eo
p
le
, y
ou
 k
no
w
, i
t'
s 
b
ec
om
es
 q
ui
te
 e
xp
en
si
ve
 a
t 
tim
es
. I
 m
ea
n 
w
e 
ge
t 
a 
fe
m
al
e 
in
to
 o
nc
e 
a 
w
ee
k 
to
 h
el
p
 w
ith
 h
ou
se
w
or
k,
 h
ou
se
 c
le
an
in
g,
 t
hi
ng
s 
lik
e 
th
at
. (
R
ob
er
t,
 9
2,
 2
 y
ea
rs
 s
in
ce
 d
ia
gn
os
is
)
A
t 
th
e 
en
d
 o
f t
he
 m
ed
ic
al
, h
e 
sa
id
 I 
p
as
se
d
 t
he
 m
ed
ic
al
, I
 w
ou
ld
n'
t 
b
e 
en
tit
le
d
 t
o 
an
y 
em
p
lo
ym
en
t 
su
p
p
or
t 
al
lo
w
an
ce
 b
ec
au
se
, a
cc
or
d
in
g 
to
 t
he
 
m
ed
ic
al
, I
 h
ad
 n
o 
d
es
cr
ip
to
rs
 o
f s
co
re
d
 p
oi
nt
s 
fo
r 
d
is
ab
ili
ty
. [
…
] W
ha
t 
it 
re
al
ly
 m
ea
nt
 w
as
 t
ha
t 
no
ne
 o
f t
he
 d
es
cr
ip
to
rs
 t
ha
t 
th
ey
 w
or
ke
d
 o
n 
to
 s
ee
 
ho
w
 il
l y
ou
 w
er
e,
 a
p
p
lie
d
 t
o 
m
e.
 […
] t
he
y’
d
 a
ns
w
er
 t
he
 q
ue
st
io
ns
 o
n 
th
e 
co
m
p
ut
er
 a
nd
 t
he
re
 w
as
 n
ot
hi
ng
 in
 t
he
re
 fo
r 
an
yb
od
y 
w
ith
 P
M
R
 a
nd
 G
C
A
. 
[…
] I
’d
 p
as
se
d
 t
he
 t
es
t,
 b
ut
 I 
p
oi
nt
ed
 o
ut
 I 
co
ul
d
 o
nl
y 
w
or
k 
fo
r 
90
 m
in
. (
P
et
er
, 7
0,
 6
 y
ea
rs
 8
 m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
I w
en
t 
an
d
 g
ot
 m
ys
el
f a
 b
ig
ge
r 
sc
re
en
 fo
r 
m
y 
te
le
vi
si
on
, a
 b
ig
ge
r 
sc
re
en
 t
el
ev
is
io
n,
 s
o 
I c
an
 w
at
ch
 t
he
 t
el
ev
is
io
n.
 (C
la
re
, 7
5,
 2
 y
ea
rs
 s
in
ce
 d
ia
gn
os
is
)
D
ri
vi
ng
W
el
l, 
I’m
, I
’m
 m
o
re
 c
au
ti
o
us
 a
ct
ua
lly
, e
sp
ec
ia
lly
 if
 I’
m
 d
ri
vi
ng
. A
lth
ou
gh
 m
y—
w
ha
t 
I s
ee
, I
 s
ee
 q
ui
te
 w
el
l n
ow
 I’
ve
 g
ot
 m
y 
ne
w
 g
la
ss
es
, b
ut
 t
he
 
ac
tu
al
 b
lin
d
 a
re
a 
is
 a
 li
tt
le
…
. I
t’s
 n
ot
 a
 p
ro
b
le
m
, b
ut
 I 
ha
ve
 t
o
 b
e 
ca
re
fu
l w
it
h 
tr
af
fi
c 
lig
ht
s 
fo
r 
in
st
an
ce
, b
ec
au
se
 I 
ca
n 
b
e 
go
in
g 
al
on
g 
an
d
 fo
r 
on
e 
b
rie
f s
ec
on
d
 t
he
 t
ra
ffi
c—
th
e 
re
d
 li
gh
t 
is
n’
t 
th
er
e.
 T
he
n 
if 
I c
ha
ng
e 
ju
st
 s
lig
ht
ly
 m
y 
ra
ng
e,
 o
r 
lo
ok
 ju
st
 s
lig
ht
ly
 t
o 
th
e 
le
ft
 o
r 
up
 o
r 
d
ow
n,
 t
he
n 
th
e 
lig
ht
 is
 
th
er
e 
an
d
 I 
kn
ow
 it
’s
 t
he
re
 a
nd
 I 
ke
ep
 m
y 
ey
e 
on
—
at
 t
ha
t 
le
ve
l t
he
n.
 (M
ar
y,
 7
2,
 2
 m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
I d
o 
d
riv
e 
lo
ca
lly
 a
nd
 s
om
e 
lo
ng
 d
is
ta
nc
e 
b
ut
, y
ou
 k
no
w
, I
, I
 d
on
’t 
d
o 
an
yt
hi
ng
 fo
r 
a 
lo
ng
 p
er
io
d
 o
f t
im
e.
 T
ha
t’s
 a
s 
a 
re
su
lt 
of
 t
he
 il
ln
es
s 
re
al
ly
, I
 t
hi
nk
. 
(B
ar
b
ar
a,
 7
1,
 2
 y
ea
rs
 1
0 
m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
It 
to
ok
 m
e 
a 
lo
ng
 t
im
e 
to
 le
ar
n 
to
 g
o 
b
ac
k 
to
 d
riv
in
g 
an
d
 I 
st
ill
 w
on
’t 
d
riv
e 
on
 t
he
 m
ot
or
w
ay
 b
ec
au
se
 it
’s
 m
y 
rig
ht
 e
ye
 t
ha
t’s
 a
ffe
ct
ed
 a
nd
 I’
m
 
fr
ig
ht
en
ed
 t
ha
t 
I s
ha
n’
t 
se
e 
ca
rs
 if
 I 
p
ul
l o
ut
. S
o 
I’m
 v
er
y 
ca
re
fu
l. 
(G
lo
ria
, 7
2,
 6
 y
ea
rs
 s
in
ce
 d
ia
gn
os
is
)
Th
e 
on
ly
 t
hi
ng
 t
ha
t 
I r
ea
lly
 m
is
s 
is
 b
ei
ng
 a
b
le
 t
o 
d
riv
e…
so
 I 
ha
ve
 t
o—
ob
vi
ou
sl
y 
ha
ve
 t
o 
re
ly
 o
n 
fr
ie
nd
s 
an
d
 fa
m
ily
. (
C
la
re
, 7
5,
 2
 y
ea
rs
 s
in
ce
 d
ia
gn
os
is
)
Ta
b
le
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Ta
b
le
 5
 
Th
ou
gh
ts
 a
nd
 fe
el
in
gs
 in
 e
ve
ry
d
ay
 li
fe
 w
ith
 g
ia
nt
 c
el
l a
rt
er
iti
s
Fr
us
tr
at
io
n
It 
is
 f
ru
st
ra
ti
ng
; t
he
re
’s
 n
o 
d
ou
b
t 
ab
ou
t 
it.
 I 
ca
n’
t 
sa
y 
it 
is
n’
t.
 (C
la
re
, 7
5,
 2
 y
ea
rs
 s
in
ce
 d
ia
gn
os
is
)
It’
s 
ve
ry
 fr
us
tr
at
in
g,
 b
ec
au
se
 y
ou
—
yo
ur
 m
in
d
 s
til
l t
hi
nk
s 
yo
u 
ca
n 
d
o 
th
in
gs
, b
ut
 a
ct
ua
lly
 […
] w
he
n 
I t
ry
, m
y 
b
od
y 
fla
gs
 o
ut
 v
er
y 
q
ui
ck
ly
. (
S
ue
, 6
7,
 3
 y
ea
rs
 
9 
m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
I g
et
 fr
us
tr
at
ed
 b
ec
au
se
 […
] I
 t
hi
nk
, '
Th
is
 h
as
 g
ot
 t
o 
b
e 
d
on
e.
' D
i n
ne
rs
 g
ot
 t
o 
st
ar
t 
an
d
 if
 I'
m
 n
ot
 w
el
l I
 s
ay
, '
C
an
 y
ou
 g
iv
e 
m
e 
…
?'
 'I
n 
a 
m
in
ut
e.
 In
 a
 
m
in
ut
e.
' I
'm
 n
ot
 t
ha
t 
ty
p
e 
of
 p
er
so
n.
 I 
w
an
t 
to
 g
et
 u
p
 a
nd
 g
et
 it
 d
on
e 
an
d
 s
or
te
d
. A
nd
 I'
m
 g
et
tin
g 
ve
ry
 fr
us
tr
at
ed
 t
ha
t 
w
ay
. (
D
or
ot
hy
, 7
8,
 2
 y
ea
rs
 1
1 
m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
O
h 
fr
us
tr
at
ed
, I
 s
up
p
os
e,
 r
ea
lly
, y
ou
 k
no
w
. I
, I
 w
an
t 
to
 b
e 
d
oi
ng
 t
hi
ng
s 
b
ut
 y
ou
 k
no
w
 v
er
y 
w
el
l t
ha
t 
yo
u 
ca
n'
t.
 (K
ei
th
, 7
1,
 3
 y
ea
rs
 6
 m
on
th
s 
d
ia
gn
os
is
)
Lo
ss
 o
f 
in
d
ep
en
d
en
ce
I c
an
't
 d
o
 t
he
 jo
b
s 
I u
se
d
 t
o
 d
o
 a
b
ou
t 
th
e 
p
la
ce
, y
ou
 k
no
w
. I
’m
 g
on
na
 h
av
e 
to
 g
et
 a
 g
ar
d
en
er
 in
 t
o 
he
lp
 m
e 
w
ith
 t
he
 g
ar
d
en
 b
ec
au
se
 it
's
 g
et
tin
g 
ov
er
gr
ow
n 
an
d
 u
m
 t
hi
ng
s 
lik
e 
th
at
 y
ou
 k
no
w
 a
nd
 jo
b
s 
ar
ou
nd
 t
he
 h
ou
se
 w
he
re
 I 
w
ou
ld
 d
o 
it 
m
ys
el
f I
'v
e 
g
o
t 
to
 g
et
 s
o
m
eo
ne
 in
 t
o
 d
o
 t
he
m
. [
…
] i
t'
s 
ju
st
 
th
at
 m
ai
nl
y 
I q
ui
te
 e
nj
o
ye
d
 d
o
in
g
 it
 m
ys
el
f 
an
d
 I 
kn
o
w
 I 
ca
n'
t 
no
w
. (
R
ob
er
t,
 9
2,
 2
 y
ea
rs
 s
in
ce
 d
ia
gn
os
is
)
Yo
u 
ju
st
 c
an
’t 
d
o 
th
in
gs
 fo
r 
yo
ur
se
lf 
an
ym
or
e 
an
d
 t
ha
t—
th
is
 is
 w
ha
t,
 t
hi
s 
is
 w
ha
t 
I h
at
e 
m
or
e 
th
an
 a
ny
th
in
g.
 […
] S
o 
it 
re
-,
 it
 r
ea
lly
 g
et
s 
yo
u 
d
ow
n—
it 
ge
t—
it 
d
oe
s 
ge
t 
yo
u 
d
ow
n 
so
m
et
im
es
 […
] i
t’s
 ju
st
 t
ha
t 
th
e,
 t
he
 t
hi
ng
s 
th
at
 y
ou
, t
ha
t 
yo
u 
ca
n’
t 
d
o 
fo
r 
yo
ur
se
lf 
th
at
 y
ou
’v
e 
al
w
ay
s 
d
on
e 
an
d
, a
nd
 y
ea
h,
 y
ou
’v
e 
go
t 
to
 k
ee
p
 o
n 
as
ki
ng
 o
th
er
 p
eo
p
le
 t
o 
d
o 
th
in
gs
 fo
r 
yo
u 
an
d
 t
ha
t,
 t
o 
b
e 
ho
ne
st
 w
ith
 y
ou
, t
ha
t 
is
 n
ot
 m
e.
 (L
au
re
nc
e,
 7
2,
 1
 y
ea
r 
7 
m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
Yo
u 
lo
se
 y
ou
r 
in
d
ep
en
d
en
ce
 w
he
n 
yo
u 
ca
n’
t 
d
riv
e 
[…
] I
 d
o 
m
is
s 
m
y 
d
riv
in
g 
re
al
ly
. (
C
la
re
, 7
5,
 2
 y
ea
rs
 s
in
ce
 d
ia
gn
os
is
)
U
na
b
le
 t
o
 c
o
p
e/
m
an
ag
e
I r
ea
lly
 d
o 
fin
d
 s
om
e 
th
in
gs
 a
 b
it 
of
 a
n 
ef
fo
rt
 […
] I
 f
ee
l p
at
he
ti
c 
at
 t
im
es
 a
nd
 it
’s
 ju
st
 n
o
t 
m
e 
to
 fe
el
 p
at
he
tic
. [
…
] I
 f
ee
l a
s 
if 
I’m
 k
in
d
 o
f 
b
ei
ng
 s
tu
p
id
 
an
d
 m
ak
in
g
 a
 f
us
s.
 T
ha
t 
I s
ho
ul
d
 b
e 
ge
tt
in
g 
on
 w
ith
 t
hi
ng
s 
an
d
 I—
an
d
 s
om
et
im
es
 I 
ju
st
 c
an
’t;
 I 
ju
st
 h
av
en
’t 
go
t 
th
e 
en
er
gy
. (
M
ar
y,
 7
2,
 2
 m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
It'
s 
ge
tt
in
g 
th
at
 I 
sa
id
 t
o 
m
y 
hu
sb
an
d
, '
I w
is
h 
I w
as
 s
ix
 fo
ot
 u
nd
er
.' 
[…
] I
'm
 g
et
tin
g 
q
ui
te
 d
ep
re
ss
ed
 w
ith
 it
 […
] I
t'
s 
ve
ry
 d
em
or
al
is
in
g 
w
he
n 
yo
u'
re
 n
ot
 t
he
 
ty
p
e 
of
 p
er
so
n 
th
at
 g
iv
es
 u
p
. [
…
] A
nd
 I 
fin
d
 it
 v
er
y 
ha
rd
 t
ha
t 
I'm
 n
ot
 c
op
in
g 
lik
e 
I u
se
d
 t
o.
 (D
or
ot
hy
, 7
8,
 2
 y
ea
rs
 1
1 
m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
I fi
nd
 t
he
 s
te
ro
id
s 
re
al
ly
, s
or
t 
of
, q
ui
te
 h
ar
d
 t
o 
co
p
e 
w
ith
 b
ec
au
se
 t
he
y’
re
—
th
ey
’r
e 
ve
ry
—
th
ey
 h
av
e 
so
m
e 
p
ec
ul
ia
r 
re
ac
tio
ns
, v
er
y,
 v
er
y 
tir
in
g.
 (R
os
e,
 7
3,
 
1 
ye
ar
 s
in
ce
 d
ia
gn
os
is
)
R
ed
uc
ed
 
co
nfi
d
en
ce
W
el
l b
o
d
y 
im
ag
e 
is
 s
om
et
hi
ng
 t
ha
t 
m
ay
 s
ee
m
 s
up
er
fi
ci
al
 b
ut
 w
he
n 
yo
u 
se
e 
yo
ur
se
lf 
co
ve
re
d
 in
 le
si
on
s 
al
l o
ve
r 
an
d
 y
ou
r 
ha
ir 
fa
lli
ng
 o
ut
 a
nd
 t
he
se
 
gh
as
tly
 b
ru
is
es
 a
ll 
ov
er
 it
's
, i
t 
d
o
es
n'
t 
m
ak
e 
yo
u 
fe
el
 g
o
o
d
. (
Ju
ne
, 7
5,
 2
 y
ea
rs
 s
in
ce
 d
ia
gn
os
is
)
I h
ad
 lo
st
 c
on
fid
en
ce
 in
 m
ys
el
f a
nd
 I 
ju
st
 d
id
 n
ot
 h
av
e 
th
e 
co
nfi
d
en
ce
. O
b
vi
ou
sl
y 
b
ec
au
se
 I'
ve
 p
ut
 w
ei
gh
t 
on
 a
s 
w
el
l a
nd
 I 
ha
d
n'
t 
b
ee
n 
to
 c
hu
rc
h 
fo
r 
a 
w
hi
le
 a
nd
, y
ou
 k
no
w
, p
eo
p
le
 a
re
 g
oi
ng
 t
o 
se
e 
th
e 
d
iff
er
en
ce
 in
 m
e 
an
d
 t
he
y'
re
 a
ll 
go
in
g 
to
 s
ay
, '
O
h,
 w
ha
t'
s 
w
ro
ng
? 
H
ow
 a
re
 y
ou
?'
 a
nd
 a
ll 
th
is
 s
or
t 
of
 
th
in
g 
an
d
 y
ou
 ju
st
 w
an
t 
to
 s
ta
y 
aw
ay
 fr
om
 p
eo
p
le
 't
ill
 y
ou
 g
et
 b
ac
k 
to
 n
or
m
al
 a
nd
 y
ou
 d
on
't
 h
av
e 
to
 a
ns
w
er
 a
ll 
th
os
e 
q
ue
st
io
ns
. [
…
] G
et
tin
g 
ho
t.
 T
ha
t 
ca
n 
af
fe
ct
 y
ou
, y
ou
r 
co
nfi
d
en
ce
 b
ec
au
se
 y
ou
 d
on
't
 w
an
t 
to
 b
e 
w
ith
 p
eo
p
le
 b
ec
au
se
 y
ou
 s
ta
rt
 t
o 
sw
ea
t 
an
d
 y
ou
r 
fa
ce
 g
oe
s 
b
rig
ht
 r
ed
 (L
in
d
a,
 6
8,
 8
 m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
O
ut
 o
f m
y 
rig
ht
 e
ye
, I
 c
an
’t 
se
e 
[…
] I
t’s
 t
ak
en
 a
ll 
m
y 
co
nfi
d
en
ce
 a
w
ay
. I
’v
e 
go
t 
no
 c
on
fid
en
ce
 a
t 
al
l. 
(S
he
ila
, 7
3,
 1
1 
m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
I f
el
t 
ve
ry
 u
na
tt
ra
ct
iv
e.
 […
] W
he
re
 I 
w
as
, y
ou
 k
no
w
, t
ha
t 
co
nfi
d
en
t,
 w
or
ki
ng
 w
om
an
 w
ho
 w
ou
ld
 ju
m
p
 in
 t
he
 c
ar
 a
nd
 g
o 
ou
t 
an
d
 s
ee
 a
ll 
th
es
e 
b
ig
 
co
rp
or
at
es
 a
nd
, y
ou
 k
no
w
, e
nj
oy
ed
 li
fe
 t
o 
fe
el
in
g 
lik
e 
a 
re
al
ly
 o
ld
, o
ld
 p
er
so
n.
 J
us
t,
 ju
st
 a
w
fu
l. 
A
w
fu
l. 
I s
ee
 t
he
 p
ho
to
s 
[…
] I
 ju
st
 lo
ok
 h
id
eo
us
. (
C
re
ss
id
a,
 
62
, 5
 y
ea
rs
 5
 m
on
th
s 
si
nc
e 
d
ia
gn
os
is
)
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help them maintain independence and retain or restore 
a sense of normality.
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